Scientists have zeroed in on a culprit that spurs damaging inflammation in the heart following a heart attack. The guilty party is a type of immune cell that tries to heal the injured heart but instead triggers inflammation ...
Jun 07, 2018
0
90
Johns Hopkins researchers report evidence from mouse studies that a "repurposed" drug that would be expected to improve the immune system response of tuberculosis patients may be increasing resistance to the antibiotic drugs ...
Sep 06, 2016
0
0
(HealthDay)—A pair of drugs offers new hope to patients with a progressive, fatal disease that robs their breath by scarring the lungs, according to clinical trial results.
May 18, 2014
0
0
Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011. ...
Jan 03, 2012
0
0
The CAPACITY study, published Online First and in an upcoming Lancet, shows that pirfenidone reduces the rate of decline of lung function in patients with idiopathic pulmonary fibrosis—a condition of unknown cause affecting ...
May 13, 2011
0
0
A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.
May 17, 2009
0
0
